Real-World Evidence Confirms Pluvicto Effectiveness When Used Before Chemotherapy, Particularly After Single ARPIs

Recent clinical data from multiple US real-world studies demonstrates that Pluvicto delivers meaningful benefits for patients with metastatic castration-resistant prostate cancer (mCRPC) when administered prior to chemotherapy—especially for those who have previously received only a single ARPI. Novartis highlighted these findings as validation of their treatment sequencing strategy in managing advanced prostate cancer.

Progression-Free Survival Results Support Early Intervention

Real-world patient data showed that chemo-naïve patients with PSMA-positive mCRPC achieved a median progression-free survival (PFS) of 13.5 months when treated with Pluvicto before transitioning to taxane-based chemotherapy. This metric provides clinicians with concrete evidence for timing treatment decisions. The consistency of these real-world outcomes with the PSMAfore clinical trial—which supported Pluvicto’s regulatory approval—strengthens confidence in the drug’s clinical utility across diverse patient populations.

ARPI Sequencing Significantly Impacts Treatment Outcomes

A critical finding emerged regarding the role of prior androgen receptor pathway inhibitors (ARPIs) in determining Pluvicto’s effectiveness. Patients who had received only a single ARPI demonstrated superior progression-free survival compared to those previously treated with multiple ARPIs. This distinction carries important implications for treatment planning, suggesting that earlier intervention with Pluvicto—before accumulating multiple lines of ARPI therapy—may optimize long-term outcomes. The data indicates that ARPI load history should influence clinicians’ decisions about when to introduce radiopharmaceutical therapy.

Market Response and Clinical Adoption

Novartis shares responded positively to the announcement, reflecting investor confidence in the drug’s real-world performance data. The convergence of controlled trial evidence (PSMAfore) with actual clinical practice outcomes validates the company’s treatment paradigm for PSMA-directed therapy in ARPIs-experienced patients, though timing of introduction appears crucial for maximizing benefit.